Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B

IONIS PHARMACEUTICALS INC

2024-Q3 EPS reported -$2.38 revenue$478,562,000

Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.
WAINUA royalty revenue $5M in Q3 ($10M YTD); SPINRAZA royalties $57M in Q3 ($152M YTD).
Olezarsen PDUFA Dec 19, 2024 for FCS; donidalorsen PDUFA Aug 21, 2025 for HAE.
Cash & investments $2.5B at Sep 30; raised ~$500M from 11.5M-share offering at $43.50.
Phase 3 ION582 for Angelman syndrome to begin H1 2025 after positive FDA end-of-Phase 2 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.